NDAORALPOWDER
Approved
Dec 1988
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Clinical Trials
3
Data completeness
4/8 — Partial
QUESTRAN LIGHT (cholestyramine) by Bristol Myers Squibb is bile-acid binding activity [moa]. First approved in 1988.
Drug data last refreshed 2d ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
QUESTRAN LIGHT is an oral powder formulation of cholestyramine, a bile-acid sequestrant approved in 1988 that works by binding bile acids in the intestine to reduce cholesterol absorption. It is indicated for hypercholesterolemia as a primary treatment and has off-label use in multiple sclerosis, nonalcoholic fatty liver disease, carotid artery stenosis, and renal impairment management. The mechanism reduces LDL cholesterol by interrupting enterohepatic circulation of bile acids.
$8KPart D
LOE ApproachingDeclining
<1% of lipid-lowering market (dominated by statins and newer agents)
Minimal commercial infrastructure; small sales force and marketing team focused on niche prescriber relationships.
Mechanism of Action
Bile-acid Binding Activity
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (3)
A Study to Evaluate the Effect of Cholestyramine on LOXO-783 in Healthy Participants
Started Jun 2023
21 enrolled
Healthy
Efficacy and Safety of Elobixibat in Combination With Cholestyramine for Nonalcoholic Fatty Liver Disease
Started Jan 2020
102 enrolled
Nonalcoholic Fatty LiverNonalcoholic Steatohepatitis
Comparison of Colesevelam Hydrogen Chloride (HCl) Powder For Oral Suspension Versus Generic Cholestyramine Through Use of the Bile Acid Sequestrant Acceptability (BASA) Scale
Started Apr 2010
42 enrolled
Healthy
Career Relevance
Working on QUESTRAN LIGHT offers limited career acceleration due to minimal market growth, zero clinical development, and eroded patent protection. Career value is primarily defensive: managing market decline, optimizing payer contracts, and exploring niche indications (MS, NAFLD) where clinical evidence gaps exist.
Worked on QUESTRAN LIGHT at Bristol Myers Squibb? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.